Switzerland · Delayed Price · Currency is CHF Basilea Pharmaceutica AG Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 11% to CHF 232.4 million in 2025, driven by Cresemba and Zevtera, with net profit at CHF 40.2 million and strong cash flow. Pipeline expansion and non-dilutive funding position the business for sustained growth, despite upcoming loss of exclusivity for Cresemba.
-
Strong H1 2025 results driven by Cresemba's robust sales and Zevtera's U.S. launch, with total revenue up 36% year-on-year. Pipeline expanded with a new oral antibiotic, and 2025 guidance raised for revenue and operating profit, despite expected product revenue decline from Pfizer supply.
Fiscal Year 2024
-
2024 saw revenue grow 32% to $208.5M, with operating profit tripling and net profit reaching $77.6M. Cresemba and Zevtera drove strong results, while the pipeline expanded with new antifungal and antibiotic assets. 2025 guidance anticipates continued growth and profitability.
-
Strong H1 2024 results driven by Cresemba growth and Zevtera U.S. approval led to raised full-year guidance. Pipeline expanded with four new anti-infective programs, and significant milestone payments are expected in H2. Debt reduction and stable expenses support a positive outlook.